Version 2.1.0 of the guideline has been released and includes revised recommendations on corticosteroids.
Version 3.0.0 of the guideline has been released and contains revised recommendations on hydroxychloroquine and hydroxychloroquine plus azithromycin. Version 3.0.1 has been released and includes endorsement from the Pediatric Infectious Diseases Society. Version 3.1.0 has been released and contains additional information on convalescent plasma as well new and updated narrative summaries of treatments undergoing evaluation. Version 3.2.0 has been released and contains a new recommendation on the use of remdesivir in patients with more moderate disease. Version 3.2.1 has been released and includes endorsement from the Pediatric Infectious Diseases Society. Version 3.3.0 has been released and contains revised and new recommendations for the use of dexamethasone and a revised recommendation against the routine use of tocilizumab. Version 3.4.0 has been released and contains a new recommendation on the use of bamlanivimab. Version 3.5.0 has been released and includes revisions to the sections on lopinavir/ritonavir, tocilizumab, and remdesivir. Version 3.5.1 has been released and includes endorsement from the Pediatric Infectious Diseases Society. Version 3.6.0 has been realeased and includes new recommendations on the use of baricitinib and an updated literature review on hydroxychloroquine. Version 3.7.0 has been released and includes two new recommendations on the use of neutralizing monoclonal antibodies. Version 3.8.0 has been released and includes two new recommendations on the use of ivermectin. Version 3.9.0 has been released and contains an updated literature review for tocilizumab. Version 3.10.0 has been released and includes additional information on study eligibility for ivermectin. Version 4.0.0 has been released and contains a revised recommendation on the use of tocilizumab. Version 4.1.0 has been released and contains a new recommendation on the use of bamlanivimab with etesevimab among ambulatory patients. Version 4.1.1 has been released and contains a revision to the number of studies found for ivermectin. Version 4.2.1 has been released and contains endorsement from the Pediatric Infectious Diseases Society. Version 4.3.0 has been released and contains a new recommendation on the use of remdesivir. Version 4.4.0 has been released and includes updated recommendations and literature summary on neutralizing antibodies. Version 4.4.1 has been released and includes endorsement from the Pediatric Infectious Diseases Society.
This update has been endorsed by the Society for Healthcare Epidemiology of America. Version 5.0.0 has been released and includes new and updated recommendations for neutralizing antibodies and ivermectin. Version 5.1.0 has been released and includes revised remarks for the use of baricitinib and new recommendations on the use of tofacitinib. Version 5.1.1 has been released and includes endorsement from the Pediatric Infectious Diseases Society. Version 5.1.2 has been released and includes endorsement from the Society of Infectious Diseases Pharmacists. This update has been endorsed by the Society for Healthcare Epidemiology of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Version 5.2.0 has been released and includes a new recommendation on the use of sarilumab. Version 5.2.1 has been released and features existing recommendations on the use of neutralizing SARS-CoV-2 antibodies separated by prophylaxis vs. This update has been endorsed by the Society for Healthcare Epidemiology of America and the Society of Infectious Diseases Pharmacists. Version 5.3.0 has been released and includes a new recommendation on the use of hydroxychloroquine as post-exposure prophylaxis. This recommendation has a moderate-not low-certainty of evidence. Version 5.3.1 has been released and contains a correction to the certainty of evidence for the new recommendation on the use of hydroxychloroquine as post-exposure prophylaxis. This update has been endorsed by the Society of Infectious Diseases Pharmacists. Version 5.4.0 has been released and contains includes revised remarks and a new evidence profile for the use of baricitinib for critically ill patients requiring invasive mechanical ventilation. Medical Education Community of Practice.Fellows-In-Training Career & Education Center.myIDSA Practice Managers Community Opt-in Form.Antimicrobial Stewardship Centers of Excellence Program.